LA JOLLA PHARMACEUTICAL CO Management's Discussion and Analysis of Financial Condition and Resultsof Operations (form 10-Q)

Published: 2022-08-15 08:06:17 ET LJPC

Business Overview

XERAVA® (eravacycline)

Product Candidates

Results of Operations

License and Other Revenue

inventory fair value step-up adjustment recorded in connection with the acquisition of Tetraphase. No such adjustment was included in costs of product sales for the three and six months ended June 30, 2022.

Cost of License and Other Revenue

Selling, General and Administrative Expense

20,035 $ 17,751 $ 2,284

Research and Development Expense

Other Income (Expense), Net

During the three months ended June 30, 2022, other income (expense), net was $3.5 million, compared to $(0.1) million for the same period in 2021. This increase is primarily due to a $3.9 million increase in the receipt of distributions in connection with the Company's Minority Interest.

Liquidity and Capital Resources

Contractual Obligations

HealthCare Royalty Partners Royalty Agreement

George Washington University

Harvard University

Paratek Pharmaceuticals, Inc.

Everest Medicines Limited

Critical Accounting Estimates

Recent Accounting Pronouncements

See Note 2 to our condensed consolidated financial statements included in Item 1 of this Quarterly Report on Form 10-Q.

--------------------------------------------------------------------------------